Craft

Advanced
  • Home
  •  / Trevi Therapeutics
Trevi Therapeutics

Trevi Therapeutics

Stock Price

$3.1

2024-10-29

Market Capitalization

$223.6 M

2024-10-29

Revenue

$14.1 M

FY, 2018

Trevi Therapeutics Summary

Company Summary

Overview
Trevi Therapeutics is a drug development company focused on developing Nalbuphine ER for the severe chronic itching condition known as pruritus. 
Type
Public
Status
Active
Founded
2011
HQ
New Haven, CT, US | view all locations
Website
http://trevitherapeutics.com/
Cybersecurity rating
Sectors

Table of Contents

Key People

  • Jennifer Good

    Jennifer Good, Co-Founder, President & CEO, Director

  • Thomas Sciascia

    Thomas Sciascia, Co-Founder and Chief Scientific Officer

    • Lisa Delfini

      Lisa Delfini, Chief Financial Officer

    • David Meeker

      David Meeker, Chairman

      LocationsView all

      1 location detected

      • New Haven, CT HQ

        United States

        195 Church St

      Trevi Therapeutics Financials

      Summary Financials

      Net income (Q1, 2026)
      ($13.2M)
      Cash (Q1, 2026)
      $19.4M
      EBIT (Q1, 2026)
      ($14.9M)
      Enterprise value
      $204.9M

      Competitors and Similar Companies

      Compare competitors

      Footer menu

      Product

      Solutions

      Resources

      Company

      © Craft.co 2026
      Share price data provided by IEX